Search

An estimated one-quarter of adults in the U.S. have nonalcoholic fatty liver disease (NAFLD), an excess of fat in liver cells that can cause chronic inflammation and liver damage, increasing the risk of liver cancer.

UT Southwestern is ranked among the top 20 medical schools for primary care and the top 25 for research in the United States, according to U.S. News & World Report’s 2023 Best Graduate Schools rankings.

A single protein can reverse the developmental clock on adult brain cells called astrocytes, morphing them into stem-like cells that produce neurons and other cell types, UT Southwestern researchers report in a PNAS study.

For three decades, scientists have debated the underlying cause of Gulf War illness (GWI), a collection of unexplained and chronic symptoms affecting veterans of the Persian Gulf War.

A stress signal received by the heart from fat could help protect against cardiac damage induced by obesity, a new study led by UT Southwestern researchers suggests. The finding, published online in Cell Metabolism, could help explain the “obesity paradox,” a phenomenon in which obese individuals

Physician researchers from UT Southwestern Medical Center have developed an innovative nanotherapeutic drug that prevents cancer from spreading to the liver.

As you drift into unconsciousness before a surgery, general anesthetic drugs flowing through your blood are putting you to sleep by binding mainly to a protein in the brain called the ɣ-aminobutyric acid type A (GABAA) receptor.

UT Southwestern Medical Center is one of 13 inaugural organizations joining a newly launched partner network of The National Academies’ Action Collaborative on Preventing Sexual Harassment in Higher Education to support evidence-based policies and practices for preventing sexual harassment.

Dallas ISD and the UT Southwestern Medical Center (UTSW) together will launch a new transformation school slated to open its doors next fall.

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non-small cell lung cancers (NSCLCs) to respond to an immune checkpoint blockade (ICB), a therapy that harnesses the immune system to fight malignant tumors.